PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
+34.19%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$710M
AUM Growth
+$710M
(+42%)
Cap. Flow
+$143M
Cap. Flow
% of AUM
20.2%
Top 10 Holdings %
Top 10 Hldgs %
64.6%
Holding
32
New
9
Increased
14
Reduced
4
Closed
5
Top Buys
| 1 |
Biogen
BIIB
|
$41.3M |
| 2 |
Akero Therapeutics
AKRO
|
$28.4M |
| 3 |
Axsome Therapeutics
AXSM
|
$23.2M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$21.7M |
| 5 |
Incyte
INCY
|
$14.5M |
Top Sells
| 1 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
$44.1M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$18.4M |
| 3 |
Arvinas
ARVN
|
$10.4M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
$7.01M |
| 5 |
United Therapeutics
UTHR
|
$4.71M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vor Biopharma
VOR
$253M
| $6.78M | 0.9% |
1,703,645
+399,345
| +31% | +$1.59M |
|
27
Milestone Pharmaceuticals
MIST
$151M
| $5.83M | 0.78% |
+634,211
| New | +$5.83M |
|
28
C4 Therapeutics
CCCC
$182M
| – | – |
-73,149
| Closed | -$552K |
|
|
29
Enanta Pharmaceuticals
ENTA
$189M
| – | – |
-148,216
| Closed | -$7.01M |
|
30
Liquidia Corp
LQDA
$2.52B
| – | – |
-850,961
| Closed | -$3.71M |
|
|
GRCL
31
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| – | – |
-783,445
| Closed | -$4.31M |
|
|
SRRA
32
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| – | – |
-801,314
| Closed | -$44.1M |
|